Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 8/20 | 0.42 |
| ▸ | CTSK | P43235 | 6/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206349 | 0.99 | S1PR1 (0.43) | NTSR1VCPCTSSCTSKS1PR1 | |
| SCHEMBL204992 | 0.89 | VCP (0.50) | NTSR1VCPCTSSCTSKS1PR1 | |
| SCHEMBL206967 | 0.89 | PTGES (0.45) | VCPALOX5MEN1NPC1RAB9A | |
| SCHEMBL205851 | 0.88 | S1PR1 (0.44) | VCPS1PR1ALOX5MEN1NPC1 | |
| SCHEMBL206889 | 0.88 | S1PR1 (0.44) | VCPS1PR1ALOX5MEN1NPC1 | |
| SCHEMBL205425 | 0.88 | S1PR1 (0.44) | VCPS1PR1ALOX5MEN1NPC1 | |
| SCHEMBL204577 | 0.87 | ALOX5 (0.46) | VCPS1PR1ALOX5MEN1NPC1 | |
| SCHEMBL206496 | 0.87 | ALOX5 (0.46) | S1PR1ALOX5MEN1NPC1RAB9A | |
| SCHEMBL206476 | 0.87 | S1PR1 (0.46) | NTSR1VCPS1PR1ALOX5MEN1 | |
| SCHEMBL208686 | 0.87 | S1PR1 (0.46) | VCPS1PR1ALOX5MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | claimed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | NTSR1 2099/4885VCP 1270/4885CTSS 1721/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | NTSR1 2099/4885VCP 1270/4885CTSS 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.